European Pharmaceutical Review Issue 4 2020
Posted: 25 August 2020 | European Pharmaceutical Review | No comments yet
Within this issue find articles on the complexities of sterility assurance, how to detect and eliminate the risk of NDMA contamination and the findings from a study involving a novel formulation of cannabinoids that has been developed to treat glioblastoma. Also included are articles on the opportunities blockchain provides for life science and healthcare businesses, as well as a discussion on how COVID-19 has impacted life sciences and biotech investment and its potential effect on investor behaviour as the pandemic subsides.
Find in the issue:
- REGULATORY INSIGHT
The trials and tribulations of the medical devices and IVD regulations
Paul Ranson, Morgan Lewis - FORMULATION, DEVELOPMENT & DELIVERY
Developing a preventive vaccine regimen to tackle Ebola
Johan Van Hoof, Janssen Vaccines
- BIOPROCESSING & BIOPRODUCTION
Regenerative medicine: a manufacturing overview
Maciej Nakoniecznik, University College London
Overview of workflows and data approaches in bioproduction – an industry perspective
Melanie Diefenbacher, Genedata - MANUFACTURING, PACKAGING & LOGISTICS
A glimpse at how Novartis’ manufacturing and supply organisation responded to COVID-19
Steffen Lang, Novartis
Beyond compliance: why embracing the FMD can transform medicine supply chain thinking
Sébastien Sliski, Zetes
The rest of this content is restricted - login or subscribe free to access
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- bi-monthly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here